We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current PAR market cap is 132.92M. The company's latest EPS is AUD -0.1677 and P/E is -2.27.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 3.7M | 8.42M | 7.84M | 7.18M | 6.11M |
| Operating Income | -13.26M | -34.78M | -40.17M | -52.91M | -59M |
| Net Income | -12.3M | -34.3M | -39.25M | -51.91M | -58.65M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 112.36M | 84.79M | 50.69M | 67.07M | 27.39M |
| Total Liabilities | 4.18M | 6.52M | 8.38M | 13.39M | 3.58M |
| Total Equity | 108.18M | 78.27M | 42.31M | 53.68M | 23.81M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -10.09M | -34.93M | -32.21M | -45.19M | -65.95M |
| Investing | 5.62M | 668k | N/A | N/A | N/A |
| Financing | 36.05M | 1M | 70k | 62.54M | 28.18M |
| Market Cap | 132.92M |
| Price to Earnings Ratio | -2.27 |
| Price to Sales Ratio | 21.71 |
| Price to Cash Ratio | 7.47 |
| Price to Book Ratio | 5.58 |
| Dividend Yield | - |
| Shares Outstanding | 349.8M |
| Average Volume (1 week) | 2.81M |
| Average Volume (1 Month) | 3.9M |
| 52 Week Change | 5.56% |
| 52 Week High | 0.61 |
| 52 Week Low | 0.165 |
| Spread (Intraday) | 0.02 (5.13%) |
| Company Name | Paradigm Biopharmaceuticals Ltd |
| Address |
level 15 melbourne, victoria 3000 |
| Website | https://www.paradigmbiopharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
